




La sindrome da Fragilità

Moving Frailty Toward Clinical Practice: NIA Intramural Frailty Science Symposium

Jeremy Walston, MD,*  Karen Bandeen-Roche, PhD,[†] Brian Buta, MHS,*
Howard Bergman, MD,[‡] Thomas M. Gill, MD,[§]  John E. Morley, MD,[¶] Linda P. Fried, MD,^{||}
Thomas N. Robinson, MD,** Jonathan Afilalo, MD,^{††} Anne B. Newman, MD,^{‡‡}
Carlos López-Otín, MD,^{§§} Rafa De Cabo, PhD,^{¶¶} Olga Theou, MD,^{|||}  Stephanie Studenski, MD,^{¶¶}
Harvey J. Cohen, MD,** * and Luigi Ferrucci, MD, PhD^{¶¶}

- **“The lack of general consensus on the language used to describe frailty, and the differing theories on the nature of frailty, present ongoing barriers to researchers and may discourage clinicians considering using frailty assessment in clinical practice”**



Moving Frailty Toward Clinical Practice: NIA Intramural Frailty Science Symposium

-the confusion as to **what frailty is** and how it can be best captured by a specific assessment....
- ...The lack of clarity may be connected in part by the use of the word “**frailty**” to indicate **disparate conceptual frameworks, risk predictors, and assessments...**
- ... Furthermore, related-and as of now, loosely defined-concepts of “**vulnerability**” and “**resiliency**” have further confused clinicians and researchers alike...

•Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/NIA Research Conference on Frailty in Older Adults

•“A state of *increased vulnerability to stress* due to age-related declines in physiologic reserves across neuromuscular, metabolic, and immune systems”



**Progressive decline in anatomical integrity
and function across multiple physiological systems**

↑
Physiological Parameter

Few examples


**Frailty as accelerated decline in anatomical integrity
and function across multiple physiological systems**


- Testosterone
- Estrogens
- IGF-1
- Cytokines and APR (higher)
- ROS / Antioxidants
- Complexity of CV reflexes

65


Age →

100





Interactions between age-related changes and chronic diseases



Clarification of conceptual frameworks for commonly used Frailty models

1. Physical Frailty

- ✓ CHS (Fried)
- ✓ SOFT
- ✓ others


2. Deficit accumulation Frailty

- ✓ CSA Frailty Index
- ✓ MPI
- ✓ Silver code
- ✓ others


3. Pre-disability state


- ✓ SPPB
- ✓ Physical Frailty and sarcopenia
- ✓ others

Physical Frailty Phenotype



The Cycle of Frailty





Frailty Status at Baseline	(n)	Died		First Hospitalization		First Fall		Worsening ADL Disability		Worsening Mobility Disability	
		3 yr %	7 yr %	3 yr %	7 yr %	3 yr %	7 yr %	3 yr %	7 yr %	3 yr %	7 yr %
Not Frail	(2469)	3	12	33	79	15	27	8	23	23	41
Intermediate	(2480)	7	23	43	83	19	33	20	41	40	58
Frail	(368)	18	43	59	96	28	41	39	63	51	71
p^{\ddagger}		<.0001		<.0001		<.0001		<.0001		<.0001	

*7-year estimates are only available for the first cohort.

†Only those evaluable for frailty are included.

‡p value is based on the 2 degree of freedom log rank test using all available follow-up.

Clarification of conceptual frameworks for commonly used Frailty models

- Physical Frailty

- CHS (Fried)
- SOFT
- others


2. Deficit accumulation Frailty

- ✓ CSA Frailty Index
- ✓ MPI
- ✓ Silver code
- ✓ others

3. Pre-disability state

- ✓ SPPB
- ✓ Physical Frailty and sarcopenia
- ✓ others

Frailty Index



Appendix 1: List of variables used by the Canadian Study of Health and Aging to construct the 70-item CSHA Frailty Index


- Changes in everyday activities
- Head and neck problems
- Poor muscle tone in neck
- Bradykinesia, facial
- Problems getting dressed
- Problems with bathing
- Problems carrying out personal grooming
- Urinary incontinence
- Mood problems
- Feeling sad, blue, depressed
- History of depressed mood
- Tiredness all the time
- Depression (clinical impression)
- Sleep changes
- Restlessness
- Memory changes
- Seizures, partial complex
- Seizures, generalized
- Syncope or blackouts
- Headache
- Cerebrovascular problems
- History of stroke
- History of diabetes mellitus
- Arterial hypertension

Ratio between the number of deficits detected and the number of conditions evaluated


- Sucking problems
- Problems going out alone
- Impaired mobility
- Musculoskeletal problems
- Bradykinesia of the limbs
- Poor muscle tone in limbs
- Poor limb coordination
- Poor coordination, trunk
- Poor standing posture
- Irregular gait pattern
- Falls
- Paranoid features
- History relevant to cognitive impairment or loss
- Family history relevant to cognitive impairment or loss
- Impaired vibration
- Tremor at rest
- Postural tremor
- Intention tremor
- History of Parkinson's disease
- Family history of degenerative disease
- Lung problems
- Respiratory problems
- History of thyroid disease
- Thyroid problems
- Skin problems
- Malignant disease
- Breast problems
- Abdominal problems
- Presence of snout reflex
- Presence of the palmomental reflex
- Other medical history

Frailty in Relation to the Accumulation of Deficits

Kenneth Rockwood^{1,2} and Arnold Mitnitski²



Kaplan–Meier medium-term survival curves (adjusted for age and sex) for individuals with different values



Clarification of conceptual frameworks for commonly used Frailty models

- Physical Frailty

- CHS (Fried)
- SOFT
- others

- Deficit accumulation Frailty

- CSA Frailty Index
- MPI
- others


3. Pre-disability state

- ✓ SPPB
- ✓ Physical Frailty and sarcopenia
- ✓ others

Short Physical Performance Battery


1.

Balance Tests




2.

Gait Speed Test




3.


Chair Stand Test



SPPB and risk of Mobility and ADL disability over 4-year FU (EPESE)




SPPB and all-cause Mortality: Systematic Review and Meta-analysis




Study	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
1.1.2 SPPB 4-6 vs 10-12				
Arnaud et al. 2015	0.52	0.19	3.1%	1.68 [1.16, 2.44]
Brown et al. 2015	0.83	0.2	3.0%	2.29 [1.55, 3.39]
Cesari et al. 2008	1.46	0.52	1.2%	4.31 [1.55, 11.93]
Cesari et al. 2013	-0.56	0.69	0.8%	0.57 [0.15, 2.21]
Chiarantini et al. 2010	0.41	0.67	0.8%	1.51 [0.41, 5.60]
Corsonello et al. 2012	0.77	0.59	1.0%	2.16 [0.68, 6.86]
Ensrud et al. 2015	0.81	0.11	3.8%	2.25 [1.81, 2.79]
Greene et al. 2014	1.07	0.34	2.0%	2.92 [1.50, 5.68]
Kim et al. 2015	1.37	0.55	1.1%	3.94 [1.34, 11.56]
Lai et al. 2014	0.73	1.17	0.3%	2.08 [0.21, 20.56]
Legrand et al. 2014	0.53	0.22	2.9%	1.70 [1.10, 2.61]
Minnecci et al. 2015	0.81	0.27	2.5%	2.25 [1.32, 3.82]
Rolland et al. 2006	0.67	0.11	3.8%	1.95 [1.58, 2.42]
Stenholm et al. 2015	1.02	0.19	3.1%	2.77 [1.91, 4.02]
Tadjbaev et al. 2014	0.74	0.25	2.6%	2.10 [1.28, 3.42]
Verghese et al. 2012	1.52	0.57	1.0%	4.57 [1.50, 13.97]
Volpato et al. 2011	1.08	1.28	0.3%	2.94 [0.24, 36.19]
Subtotal (95% CI)			33.0%	2.14 [1.92, 2.39]
Heterogeneity: Tau ² = 0.00; Chi ² = 15.25, df = 16 (P = 0.51); I ² = 0%				
Test for overall effect: Z = 13.72 (P < 0.00001)				

Study	log[Odds Ratio]	SE	Weight	Odds Ratio IV, Random, 95% CI
1.1.3 SPPB 7-9 vs 10-12				
Arnaud et al. 2015	0.31	0.17	3.3%	1.36 [0.98, 1.90]
Brown et al. 2015	0.26	0.17	3.3%	1.30 [0.93, 1.81]
Cesari et al. 2008	0.47	0.55	1.1%	1.60 [0.54, 4.70]
Cesari et al. 2013	-1.08	0.8	0.6%	0.34 [0.07, 1.63]
Chiarantini et al. 2010	-0.14	0.68	0.8%	0.87 [0.23, 3.30]
Corsonello et al. 2012	0.47	0.62	0.9%	1.60 [0.47, 5.39]
Ensrud et al. 2015	0.24	0.12	3.7%	1.27 [1.00, 1.61]
Greene et al. 2014	0.86	0.19	3.1%	2.36 [1.63, 3.43]
Kim et al. 2015	0.67	0.44	1.5%	1.95 [0.82, 4.63]
Lai et al. 2014	1.39	0.39	1.7%	4.01 [1.87, 8.62]
Legrand et al. 2014	0.47	0.19	3.1%	1.60 [1.10, 2.32]
Minnecci et al. 2015	0.21	0.2	3.0%	1.23 [0.83, 1.83]
Rolland et al. 2006	0.32	0.1	3.8%	1.38 [1.13, 1.68]
Stenholm et al. 2015	0.46	0.16	3.4%	1.58 [1.16, 2.17]
Tadjbaev et al. 2014	0.47	0.23	2.8%	1.60 [1.02, 2.51]
Verghese et al. 2012	0.62	0.32	2.1%	1.86 [0.99, 3.48]
Volpato et al. 2011	0.3	1.2	0.3%	1.35 [0.13, 14.18]
Subtotal (95% CI)			38.3%	1.50 [1.32, 1.71]
Heterogeneity: Tau ² = 0.02; Chi ² = 21.79, df = 16 (P = 0.15); I ² = 27%				
Test for overall effect: Z = 6.29 (P < 0.00001)				



The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome



The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome

Table 4. Multivariable Analysis Including Scales of Frailty and Physical Performance and Incremental Value

	Adjusted OR (95% CI)*	Δ C-Statistic	p Value	IDI	p Value	NRI	p Value
MACCE							
SPPB	0.79 (0.70–0.89)	0.044	.04	0.054	.001	0.752	<.0001
Columbia	1.17 (1.03–1.33)	0.019	.2	0.016	.2	0.248	.1
Edmonton	1.34 (1.15–1.56)	0.017	.4	0.073	<.0001	0.505	.001
Grip strength (kg)	0.96 (0.92–0.99)	0.008	.6	0.018	.04	0.316	.052
Fried	1.36 (1.04–1.79)	0.011	.5	0.019	.02	0.319	.047
Rockwood CFS	1.07 (0.76–1.49)	0.001	.9	0.001	.4	0.100	.5
MPI	1.61 (2.70–9.61)	0.020	.1	0.020	.1	0.277	.08
All-cause mortality							
SPPB	0.74 (0.63–0.85)	0.063	.02	0.061	<.0001	1.022	<.0001
Columbia	1.13 (0.97–1.30)	0.005	.5	0.013	.05	0.012	.9
Edmonton	1.33 (1.13–1.56)	0.037	.07	0.045	.004	0.646	.0003
Grip strength (kg)	0.98 (0.94–1.02)	–0.008	.4	0.010	.01	0.358	.047
Fried	1.58 (1.14–2.18)	0.020	.3	0.033	.002	0.371	.035
Rockwood CFS	1.34 (0.94–1.92)	0.005	.7	0.015	.08	0.420	.017
MPI	1.25 (0.01–113)	–0.001	.5	0.0002	.78	–0.061	1


Note: CFS = Clinical frailty scale; IDI = Integrated discrimination improvement; MACCE = Major adverse cardio cerebrovascular event; MPI = Multidimensional prognostic index; NRI = Net reclassification improvement; OR = Odds ratio; SPPB = Short physical performance battery.

*Multivariable analysis obtained after the insertion of the scale in the baseline model (Table 3).

Δ C-Statistic, IDI, NRI: the values are referred for the comparison between the baseline model (Table 3) and the same model with the addition of frailty scale.


The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome

A: MACCE



	C-statistics (95%CI)	Δ C-Statistic	IDI	NRI
GRACE	0.620 (0.581-0.663)			
GRACE + SPPB	0.763 (0.726-0.801)	0.143	0.083 (p<0.001)	0.853 (p<0.001)
TIMI	0.610 (0.575-0.645)			
TIMI + SPPB	0.768 (0.736-0.803)	0.158	0.083 (p<0.001)	0.692 (p<0.001)


B: All-cause mortality




	C-statistics (95%CI)	Δ C-Statistic	IDI	NRI
GRACE	0.640 (0.601-0.683)			
GRACE + SPPB	0.816 (0.777-0.859)	0.176	0.115 (p<0.001)	1.050 (p<0.001)
TIMI	0.651 (0.586-0.656)			
TIMI + SPPB	0.879 (0.814-0.884)	0.228	0.102 (p<0.001)	0.937 (p<0.001)

Ability to discriminate haemorrhagic events of risk scores and scales of frailty or physical performance

	BARC 3-5		BARC 2	
	C-statistic (95%CI)	p-value	C-statistic (95%CI)	p-value
Risk scores				
Paris	0.74 (0.61-0.86)	0.002	0.52 (0.46-0.57)	0.817
PRECISE-DAPT	0.79 (0.66-0.91)	<0.001	0.55 (0.50-0.61)	0.332
BleeMACS	0.77 (0.60-0.93)	<0.001	0.54 (0.50-0.60)	0.434
Scales of frailty/physical performance				
SPPB	0.75 (0.64-0.86)	0.002	0.53 (0.47-0.58)	0.632
Columbia	0.67 (0.54-0.80)	0.013	0.53 (0.48-0.59)	0.555
Edmonton	0.75 (0.62-0.89)	<0.001	0.50 (0.44-0.55)	0.961
Grip strength, (Kg)	0.64 (0.53-0.76)	0.088	0.57 (0.51-0.62)	0.189
Fried	0.66 (0.55-0.78)	0.067	0.55 (0.50-0.61)	0.343
Rockwood CFS	0.71 (0.58-0.84)	0.005	0.57 (0.52-0.62)	0.225
MPI	0.60 (0.44-0.76)	0.243	0.56 (0.51-0.61)	0.267





Using Frailty models in clinical practice:

1. Frailty as a preclinical state: a condition that can be prevented, slowed or even reversed
2. Frailty as a prognostic and stratification factor that orients the treatment plan
3. Use different model according to the clinical aim